Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-Xa assays.
Författare
Summary, in English
Apixaban is an oral direct factor Xa inhibitor developed for prophylaxis and treatment of thromboembolic disorders. Laboratory monitoring is not necessary, but the effects on common coagulation reagents and assays are clinically valuable information.
Avdelning/ar
Publiceringsår
2014
Språk
Engelska
Sidor
1545-1553
Publikation/Tidskrift/Serie
Journal of Thrombosis and Haemostasis
Volym
12
Issue
9
Länkar
Dokumenttyp
Artikel i tidskrift
Förlag
Wiley-Blackwell
Ämne
- Cardiac and Cardiovascular Systems
Status
Published
Forskningsgrupp
- Clinical Chemistry, Malmö
ISBN/ISSN/Övrigt
- ISSN: 1538-7933